Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial

Takeda's Zasocitinib Outperforms Sotyktu in Phase 3 Psoriasis Trial

Takeda's investigational oral psoriasis drug, zasocitinib, significantly outperformed Bristol Myers Squibb’s Sotyktu in a Phase 3 study. Treatment with zasocitinib resulted in complete skin clearance in over 35% of patients at 16 weeks, which was more than 2.5 times the response rate for Sotyktu. This success positions Takeda for a regulatory filing with the FDA and other global health authorities starting this fiscal year. The drug, designed with AI, targets the TYK2 protein and was acquired from Nimbus Therapeutics for $4 billion.

• Superior Efficacy in Head-to-Head Trial: Zasocitinib demonstrated superior efficacy against Bristol Myers Squibb’s Sotyktu in a Phase 3 psoriasis study. At 16 weeks, over 35% of patients treated with zasocitinib achieved complete skin clearance, a response rate more than 2.5 times higher than Sotyktu. This significant separation in efficacy was observed as early as week 8 and extended to key secondary outcomes like PASI 90 response, reinforcing its potential for rapid and durable skin clearance.
• Mechanism of Action and Strategic Acquisition: Zasocitinib, an AI-designed oral pill, functions by targeting the TYK2 protein and maintaining IL-23 inhibition for 24 hours, which is critical for its therapeutic effect in inflammatory conditions. Takeda strategically acquired this promising asset from Nimbus Therapeutics in December for $4 billion, outbidding numerous biopharmaceutical companies, underscoring the drug's perceived value and innovative design.
• Clear Regulatory Path and Market Redefinition: Following these compelling head-to-head Phase 3 results, Takeda is poised to submit a drug application for zasocitinib with the FDA and other global health authorities, commencing this fiscal year (April 1 through March 31). Industry analysts project the oral psoriasis market could exceed $5 billion by 2030, with these data validating zasocitinib's potential to redefine this market and de-risk its regulatory approval.

TYK2 Inhibition: Zasocitinib's Novel Approach to Psoriasis Treatment

Over the past three years, several novel mechanisms of action have emerged for psoriasis treatment, representing significant advances beyond traditional therapies. These emerging approaches target diverse pathophysiological pathways and offer new therapeutic options for patients with varying disease severity and treatment preferences.

• TYK2 inhibition - Deucravacitinib, a first-in-class oral TYK2 inhibitor, binds to the regulatory domain of TYK2 and inhibits signaling of IL-23, IL-12, and type I interferons, achieving PASI 75 in nearly 60% of patients at 16 weeks with superior efficacy compared to apremilast

• Phosphodiesterase type 4 (PDE4) inhibition - Roflumilast represents a novel topical non-steroidal agent approved for plaque psoriasis in patients aged 12 years and older, with various new formulations under clinical investigation

• Aryl hydrocarbon receptor (AhR) modulation - Tapinarof, approved for adult psoriasis and currently studied for pediatric use, targets different pathogenic pathways than conventional treatments through AhR modulation

• Oral IL-23 receptor antagonism - Icotrokinra, a selective interleukin-23 receptor antagonist, significantly reduces PASI scores in moderate-to-severe plaque psoriasis with oral administration offering improved convenience and adherence

• Dual IL-17A and IL-17F inhibition - Bimekizumab targets both IL-17A and IL-17F, demonstrating strong efficacy with real-world drug survival rates of 82.4% at 24 months and mean PASI score reduction from 15.5 to 1.4

• GLP-1 receptor agonism - GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists exert immunomodulatory effects by attenuating pro-inflammatory cytokine signaling while promoting anti-inflammatory pathways

• Transient Receptor Potential (TRP) channel modulation - Multiple TRP subtypes (TRPV1, TRPV3, TRPV4, TRPV6, TRPC6, TRPM8) involved in keratinocyte differentiation, immune cell activation, and sensory neuron stimulation represent promising targets for novel therapies

• Vascular normalization strategies - Emerging approaches focus on targeting excessive angiogenesis and vascular alterations in dermal blood vessels through modulation of human dermal microvascular endothelial cells

Zasocitinib's Potential to Redefine the Oral Psoriasis Market

The psoriasis treatment landscape has undergone significant transformation over the past five years, with biologics and targeted synthetic DMARDs achieving substantially better clinical and radiographic outcomes compared to traditional NSAIDs and conventional synthetic DMARDs. Network meta-analyses from 2022-2023 involving over 62,000 participants identified four biologics with the highest efficacy for achieving PASI 90: infliximab, bimekizumab, ixekizumab, and risankizumab, all demonstrating similar clinical effectiveness when compared against each other. Anti-IL17 treatments have emerged as particularly superior, showing higher PASI 90 achievement rates compared to all other intervention classes, while the therapeutic armamentarium has expanded with multiple drug classes including IL-17 inhibitors, IL-23 inhibitors, and small molecule inhibitors such as RORγt and ROCK2 inhibitors.

Real-world evidence from 2024-2026 has validated the exceptional performance of newer biologics in clinical practice. Risankizumab demonstrated remarkable efficacy in a Saudi Arabian registry study, with PASI scores decreasing from 25.49 at baseline to 0.358 by week 52, representing a 98.5% reduction. Bimekizumab, the latest IL-17A and IL-17F inhibitor, showed 28.4% of patients achieving PASI 100 at just four weeks in real-world studies, while tildrakizumab consistently achieved PASI response rates exceeding 90% at 52 weeks across multiple studies. Long-term data for ixekizumab revealed drug survival of 65.5% at 260 weeks with sustained high response rates, demonstrating the durability of modern biologic therapies.

Despite these therapeutic advances, significant challenges persist in optimizing psoriasis management. Treatment access remains highly variable, with pronounced barriers related to geographic location, socioeconomic status, and healthcare infrastructure—rural patients face particularly limited access to dermatologists compared to urban counterparts. Advanced therapy utilization remains surprisingly low across all states at less than 17%, and the field continues to grapple with difficult-to-treat disease presentations, secondary treatment failures, and lack of consensus on treatment withdrawal protocols. Additionally, special populations such as elderly patients require careful consideration, as studies show increased adverse events and lower drug survival rates, highlighting the need for personalized treatment approaches in this evolving therapeutic landscape.

A New Oral TYK2 Leader Emerges in Psoriasis

The recent Phase 3 triumph for Takeda's investigational oral psoriasis drug, zasocitinib, marks a pivotal moment in the treatment landscape for moderate-to-severe plaque psoriasis. By demonstrating significantly higher rates of complete skin clearance compared to Bristol Myers Squibb's Sotyktu, zasocitinib is poised to set a new benchmark for oral therapies. This success not only validates Takeda's substantial $4 billion acquisition of the AI-designed TYK2 inhibitor but also underscores the immense potential of this targeted pathway in autoimmune diseases.

For patients, the prospect of an oral medication offering such high levels of efficacy, particularly 'complete skin clearance,' is a compelling development. It could offer a convenient and highly effective alternative to injectable biologics or less potent oral options. However, as with any emerging therapy, a comprehensive understanding of zasocitinib's long-term safety and durability will be crucial. Existing evidence for deucravacitinib highlights the importance of sustained efficacy and a consistent safety profile over several years, and similar data will be essential for zasocitinib to solidify its position.

Strategically, Takeda is now positioned to become a formidable competitor, potentially disrupting the market currently led by Sotyktu. This will undoubtedly intensify the competitive dynamics, prompting Bristol Myers Squibb to further differentiate Sotyktu, perhaps by emphasizing its extensive real-world data, established safety record, or expanding its indications. Furthermore, the literature suggests that patient characteristics like age and BMI can influence response rates to TYK2 inhibitors. Future data on zasocitinib's performance across diverse patient subgroups, including those with prior biologic exposure, will be vital in defining its precise role in personalized psoriasis care. This development signals a vibrant future for oral small molecules in psoriasis, promising enhanced patient choice and potentially higher treatment expectations.